pct-valuation-dcf-report.docx

1018-00009 · Client 1018 · Economic Analysis

pct-valuation-dcf-report.docx DOCUMENT M&A / Corporate

82 / 176 ← → ✕

PRIVILEGED AND CONFIDENTIAL PREPARED AT THE DIRECTION OF COUNSEL UNDER KOVEL ARRANGEMENT ATTORNEY-CLIENT PRIVILEGE AND WORK PRODUCT DOCTRINE APPLY

Platform Contribution Transaction Valuation Analysis

Income Method / Discounted Cash Flow Approach

Penterra Pharmaceuticals Corp.

Cost-Sharing Arrangement with Penterra Biopharma International DAC

Prepared by:

Whitmore Valuation Group LLC 200 Ashbury Asset Advisors, Suite 700 Boston, MA 02109

Lead Economist: Dr. Helena Vasquez, Ph.D. Managing Director

Supporting Economist: Dr. Rohan Chakrabarti, Ph.D. Senior Director

Prepared at the Direction of Counsel:

Calderwood & Harkness LLP 1735 Market Street, Suite 3100 Philadelphia, PA 19103

Leonard Cross, Partner (Responsible Attorney) Garrett Simmons, Associate (Lead Associate)

December 2022

C&H Matter Number 1018-00009-KV

CONFIDENTIAL — PRIVILEGED AND CONFIDENTIAL Prepared at the Direction of Counsel Under Kovel Arrangement Attorney-Client Privilege and Work Product Doctrine Apply This document and its contents are protected from disclosure to third parties under the attorney-client privilege and the work product doctrine.

I. EXECUTIVE SUMMARY

Whitmore Valuation Group LLC ("WVG") was retained by Calderwood & Harkness LLP ("C&H"), outside tax counsel to Penterra Pharmaceuticals Corp. ("PPC"), under a Kovel arrangement (Kovel letter dated June 20, 2022, reference C&H Matter No. 1018-00009-KV), to perform an independent economic analysis of the platform contribution transaction ("PCT") payment made by Penterra Biopharma International DAC ("PBI") to PPC on July 1, 2012, in connection with a qualified cost-sharing arrangement ("CSA") entered into between PPC and PBI on that same date. This report sets forth WVG's analysis, methodology, findings, and conclusions.

The PCT payment of $312,000,000 represented PBI's buy-in to PPC's pre-existing pharmaceutical intellectual property portfolio, which consisted primarily of clinical-stage and approved oncology compounds, in exchange for PBI's right to develop and exploit that intellectual property outside the Americas (defined as North America, Central America, South America, and the Caribbean, collectively the "Americas"). The IP portfolio at the PCT date included, among other compounds, Veritaxol (an approved oncology product in early commercialization), Imvara (an immunology compound in late-stage development), and Cerulon (a rare-disease compound in early-stage development), as well as several smaller pipeline assets. The PCT payment was calculated at the time of the transaction using the income method under a discounted cash flow ("DCF") approach, as contemplated by Treasury Regulation § 1.482-7(g)(4), and was documented in contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP.

The Internal Revenue Service ("IRS"), through its Large Business & International ("LB&I") Division, Northeast Transfer Pricing Practice (Exam Team LB&I-NE-TP-2022-00641), has challenged the PCT valuation in connection with the examination of PPC's consolidated federal income tax returns for the tax years ending December 31, 2017, 2018, 2019, and 2020. While the tax year in which the PCT payment was made (2012) is outside the examination period, the IRS has used the asserted PCT undervaluation as a basis for recharacterizing PBI's ongoing cost-sharing ratios and related royalty rates for the 2017–2020 tax years. Specifically, the IRS asserts that the $312,000,000 PCT payment undervalued the pre-existing IP by approximately $540,000,000, proposing that the PCT should have been valued at $852,000,000 using an income method with a lower weighted average cost of capital ("WACC") of 7.2% and different revenue projections. This asserted undervaluation forms part of the basis for $380,400,000 in net proposed adjustments to PPC's taxable income under Internal Revenue Code ("IRC") § 482, as set forth in the Notice of Proposed Adjustment ("NOPA") dated October 12, 2023.

WVG performed an independent analysis of the PCT valuation using the income method / DCF approach prescribed by Treas. Reg. § 1.482-7(g)(4). WVG's analysis is based on revenue projections prepared as of July 1, 2012, reflecting information reasonably available at that date, a detailed cost structure analysis consistent with PBI's actual and projected operating profile, and a risk-adjusted WACC of 9.8%, derived from a rigorous build-up methodology incorporating the Capital Asset Pricing Model ("CAPM"), an industry-specific equity risk premium, beta derived from comparable specialty pharmaceutical and biotechnology companies, and appropriate size and company-specific risk premiums reflecting PBI's status as a newly incorporated entity with limited personnel and no independent operating history.

Based on WVG's analysis, the arm's-length range for the PCT payment is $278,000,000 to $361,000,000. This range was established by varying key inputs — including the discount rate, revenue growth assumptions, clinical success probability adjustments, and terminal value assumptions — within reasonable bounds supported by market data, industry benchmarks, and economic analysis. The $312,000,000 PCT payment falls squarely within this arm's-length range, at approximately the 60th percentile, confirming that the payment satisfies the arm's-length standard under IRC § 482 and Treas. Reg. § 1.482-7(g)(4).

WVG's principal conclusions are as follows:

1. The $312,000,000 PCT payment is within the arm's-length range of $278,000,000 to $361,000,000 and satisfies the arm's-length standard under IRC § 482 and Treas. Reg. § 1.482-7.

2. The IRS's proposed PCT valuation of $852,000,000, based on a WACC of 7.2% and inflated revenue projections, is not within the arm's-length range and is not supportable under the best method rule set forth in Treas. Reg. § 1.482-1(c).

3. The $540,000,000 delta asserted by the IRS is attributable primarily to: (a) an inappropriately low discount rate that fails to account for pharmaceutical-specific and company-specific risk factors, and (b) revenue projections that incorporate impermissible hindsight by effectively embedding knowledge of actual product successes that was not available at the PCT date.

4. The PCT valuation is internally consistent with WVG's parallel analyses of the legacy IP royalty rate (4.5%) under the comparable uncontrolled transaction ("CUT") method and PBI's operating margins under the comparable profits method ("CPM") / transactional net margin method ("TNMM"), further confirming the arm's-length character of the PPC-PBI transfer pricing framework.

II. ENGAGEMENT AND SCOPE

II.A. Engagement Background

Penterra Pharmaceuticals Corp. PPC is a corporation organized under the laws of the State of Delaware, publicly traded on the Nasdaq Global Select Market under the ticker symbol "PPCA," with its principal executive offices located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceutical and biotechnology company focused on the discovery, development, manufacturing, and commercialization of innovative therapeutics in three principal therapeutic areas: oncology, immunology, and rare-disease therapeutics. For the fiscal year ended December 31, 2020, PPC reported consolidated annual revenue of approximately $6.82 billion and pre-tax income of approximately $1.47 billion. As of the same date, PPC employed approximately 14,500 individuals globally, including approximately 3,200 in research and development functions, 4,800 in manufacturing and supply chain operations, and 6,500 in commercial, medical affairs, regulatory, and administrative roles.

PPC's product portfolio consists of more than 25 marketed products across the oncology, immunology, and rare-disease segments, with a pipeline of approximately 40 compounds in various stages of clinical and pre-clinical development. PPC's lead product, Veritaxol, is a first-in-class oncology compound that achieved global net sales of $3.12 billion in fiscal year 2020, making it one of the top-selling oncology products globally. Imvara, an immunology product that received U.S. Food and Drug Administration approval in 2015, generated global net sales of $1.87 billion in fiscal year 2020. Cerulon, a rare-disease therapeutic that received orphan drug designation and regulatory approval in key markets between 2016 and 2018, generated global net sales of $620 million in fiscal year 2020.

Penterra Biopharma International DAC. PBI is a Designated Activity Company organized under the laws of Ireland, registered with the Companies Registration Office of Ireland (CRO Number 511203), with its registered office located at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI was incorporated on March 15, 2012, approximately three and one-half months before the effective date of the CSA. PBI functions as the intellectual property holding company and commercial principal for the development and commercialization of PPC products outside the Americas. In this capacity, PBI manages contract manufacturing arrangements, distribution partnerships, regulatory filings, and pricing and market access strategies across approximately 68 country markets in the Europe, Middle East, and Africa ("EMEA") and Asia-Pacific ("APAC") regions.

PBI is a wholly-owned subsidiary of Penterra Holdings Luxembourg S.à r.l. ("PHL"), a société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg, with its registered office at 14, rue Aldringen, L-1118 Luxembourg (Registre de Commerce et des Sociétés, Luxembourg, No. B 168452). PHL is treated as a disregarded entity for U.S. federal income tax purposes. PHL is, in turn, 100% owned by PPC. Accordingly, PBI is an indirect, wholly-owned subsidiary of PPC, and PPC, PHL, and PBI are related parties within the meaning of IRC § 482 and the regulations thereunder.

IRS Examination. The IRS opened an examination of PPC's consolidated federal income tax returns for the tax years ending December 31, 2017, 2018, 2019, and 2020, by issuance of Letter 2205-A dated May 16, 2022. The examination is being conducted by the IRS LB&I Division, Northeast Transfer Pricing Practice, under Exam Team designation LB&I-NE-TP-2022-00641. As part of the examination, the IRS has challenged the valuation of the PCT payment and the related cost-sharing ratios applicable to the 2017–2020 tax years. The IRS's position, as set forth in the NOPA dated October 12, 2023, asserts that the $312,000,000 PCT payment undervalued the pre-existing IP by approximately $540,000,000, and that the correct PCT value under the income method is $852,000,000. The IRS has used this asserted undervaluation to recharacterize the cost-sharing ratios and to propose net adjustments totaling $380,400,000 to PPC's taxable income for the 2017–2020 tax years under IRC § 482.

Retention of WVG. WVG was retained by C&H, PPC's outside tax counsel, pursuant to a Kovel arrangement (Kovel letter dated June 20, 2022, reference 1018-00009-KV) to perform an independent economic analysis of the PCT payment and related transfer pricing issues. Under the Kovel arrangement, WVG's work product is prepared at the direction of counsel and is subject to the protections of the attorney-client privilege and the work product doctrine. See United States v. Kovel, 296 F.2d 918 (2d Cir. 1961).

II.B. Scope of Assignment

WVG was engaged to perform the following tasks:

1. PCT Valuation. Perform an independent valuation of the pre-existing intellectual property contributed to the CSA as of the PCT date (July 1, 2012) using the income method / DCF approach as prescribed by Treas. Reg. § 1.482-7(g)(4). This valuation encompasses the development and application of a DCF model incorporating product-level revenue projections, cost structure analysis, terminal value determination, and an appropriate risk-adjusted discount rate.

2. Arm's-Length Evaluation. Evaluate the appropriateness of the $312,000,000 PCT payment within the arm's-length standard, as articulated in Treas. Reg. § 1.482-1(b), by establishing an arm's-length range for the PCT value and determining whether the actual payment falls within that range.

3. Critique of IRS Valuation. Assess and critique the IRS economist's income-method valuation of $852,000,000, including the specific inputs employed by Dr. Alan Washburne, with particular focus on the IRS's discount rate (7.2% WACC), revenue projections, clinical success probability assumptions, and terminal value methodology.

4. Arm's-Length Range Determination. Determine an arm's-length range for the PCT value by performing sensitivity analyses across key valuation inputs, including the discount rate, revenue growth assumptions, and probability-weighting factors for clinical-stage compounds.

5. Consistency Analysis. Evaluate the internal consistency of the PCT valuation with WVG's parallel analyses of the legacy IP royalty rate (CUT method) and PBI's operating margins (CPM/TNMM), to confirm that the overall PPC-PBI transfer pricing framework reflects arm's-length results.

This report sets forth the results of WVG's analysis and constitutes WVG's work product prepared at the direction of C&H under the Kovel arrangement. This report is subject to attorney-client privilege and work product protection and is not intended for distribution to any party other than PPC, C&H, and their authorized representatives, except as may be required in connection with the IRS examination or related proceedings.

II.C. Information Sources and Materials Reviewed

In performing the analysis set forth in this report, WVG reviewed the following categories of documents and materials. A complete list of specific documents reviewed is set forth in Appendix A.

CSA and Related Agreements. The cost-sharing arrangement agreement between PPC and PBI, effective July 1, 2012, together with all subsequent amendments thereto. The CSA agreement defines the scope of the arrangement, the contributed IP, the cost-sharing methodology, the reasonably anticipated benefits ("RAB") calculations, and the PCT payment terms.

Original PCT Valuation. The contemporaneous PCT valuation report prepared by Crestfield & Associates LLP (Susan Lam, Transfer Pricing Partner; Martin Ogilvy, Engagement Partner), dated June 2012, which formed the basis for the $312,000,000 PCT payment. WVG reviewed this report in its entirety, including the underlying DCF model, revenue projections, discount rate analysis, and supporting workpapers.

Financial Statements and Tax Returns. PPC's consolidated financial statements (audited) and U.S. federal income tax returns (Forms 1120) for the tax years 2012 through 2020. PBI's Irish statutory financial statements and Irish corporate tax returns for the same period. These documents provided the basis for WVG's analysis of actual revenues, costs, profitability, and cost-sharing calculations.

Product-Level Revenue Data. Detailed product-level revenue data for Veritaxol, Imvara, Cerulon, and other CSA products, disaggregated by territory (Americas vs. non-Americas), for each year from 2012 through 2020. This data was provided by PPC's finance department and was reconciled to PPC's and PBI's financial statements.

R&D Cost Pool Data. Data relating to the qualified research and development costs included in the CSA cost pool for each of the examination years: $487.3 million (2017), $523.8 million (2018), $561.2 million (2019), and $598.4 million (2020).

PBI Operational Data. PBI headcount data (52 employees in 2012, growing to 185 employees in 2020), organizational charts, job descriptions for key personnel, PBI board of directors meeting minutes (42 meetings held in Dublin over the 2017–2020 period), and PBI regulatory expenditure records (€47.2 million cumulative for 2017–2020).

IRS Materials. The NOPA dated October 12, 2023, including the economic analysis prepared by Dr. Alan Washburne, IRS economist. WVG also reviewed correspondence between the IRS examination team and PPC/C&H relating to the PCT valuation and cost-sharing issues.

Industry Publications and Market Data. Pharmaceutical industry publications, market research reports (Kestrel Industries, Tidewater Holdings, Harborline Services Inc.), clinical trial databases (ClinicalTrials.gov), patent databases, and comparable pharmaceutical company financial data. WVG also utilized WVG's proprietary benchmarking databases, which contain financial and operational data for over 500 pharmaceutical, biotechnology, and life sciences companies globally.

Comparable Transaction Databases. WVG reviewed pharmaceutical licensing and collaboration transaction databases (Medtrack, Calderon Data Systems, RoyaltySource) to identify comparable uncontrolled transactions for benchmarking purposes in connection with the CUT analysis of the legacy IP royalty rate.

III. LEGAL AND REGULATORY FRAMEWORK

III.A. IRC § 482 and the Arm's-Length Standard

Section 482 of the Internal Revenue Code grants the Secretary of the Treasury broad authority to distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among two or more organizations, trades, or businesses that are owned or controlled directly or indirectly by the same interests, if the Secretary determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any such organizations, trades, or businesses. IRC § 482. The legislative purpose underlying Section 482 is to place commonly controlled taxpayers on a tax parity with uncontrolled taxpayers by determining the true taxable income of each controlled taxpayer. See Treas. Reg. § 1.482-1(a)(1).

The regulations under Section 482 implement the arm's-length standard as the governing principle for evaluating controlled transactions. Treasury Regulation § 1.482-1(b)(1) provides that, in determining the true taxable income of a controlled taxpayer, the standard to be applied in every case is that of a taxpayer dealing at arm's length with an uncontrolled taxpayer. A controlled transaction meets the arm's-length standard if the results of the transaction are consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances. Treas. Reg. § 1.482-1(b)(1). The arm's-length standard requires that controlled transactions produce results that are economically consistent with those that would have been achieved by unrelated parties acting in their own economic self-interests.

The arm's-length result is determined under the "best method rule" set forth in Treasury Regulation § 1.482-1(c). Under the best method rule, the arm's-length result of a controlled transaction must be determined under the method that, under the facts and circumstances, provides the most reliable measure of an arm's-length result. Treas. Reg. § 1.482-1(c)(1). In selecting the best method, the reliability of the result is determined by the degree of comparability between the controlled transaction and any uncontrolled comparables, and the quality of the data and assumptions used in the analysis. Id. The regulations do not establish a strict hierarchy among the specified methods; rather, the method that provides the most reliable result in a particular case is the method that should be applied. Treas. Reg. § 1.482-1(c)(2).

Additionally, the regulations provide for the establishment of an arm's-length range, which consists of the results derived from the application of a transfer pricing method to two or more uncontrolled transactions of similar comparability and reliability. Treas. Reg. § 1.482-1(e)(2). Where the controlled taxpayer's result falls within the arm's-length range, the IRS will not make an allocation under Section 482. Treas. Reg. § 1.482-1(e)(1). Conversely, where the taxpayer's result falls outside the arm's-length range, the IRS may adjust the taxpayer's result to a point within the range. Id.

III.B. Cost-Sharing Arrangements Under Treas. Reg. § 1.482-7

Treasury Regulation § 1.482-7 provides specific rules for qualified cost-sharing arrangements among controlled participants. A qualified CSA is an arrangement under which two or more controlled participants share the costs and risks of developing intangibles in proportion to their reasonably anticipated shares of the benefits from exploiting those intangibles. Treas. Reg. § 1.482-7(a), (b). A CSA that satisfies the requirements of the regulations is treated as producing results consistent with the arm's-length standard if the cost-sharing payments, PCT payments, and other terms of the arrangement are consistent with the regulations.

When a participant in a CSA makes available pre-existing resources, capabilities, or rights ("external contributions") to the CSA, the other participants must make platform contribution transaction payments to compensate the contributing participant for the value of those contributions. Treas. Reg. § 1.482-7(g). The PCT payment is the arm's-length compensation for the economic value of the external contributions made available to the CSA. The regulations contemplate that the PCT payment reflects the value of the pre-existing intangibles as of the date of the CSA, considering the income that those intangibles are reasonably anticipated to generate for the non-contributing participant.

Treasury Regulation § 1.482-7(g)(4) describes the income method for valuing PCTs. Under the income method, the PCT payment is the present value of the stream of reasonably anticipated residual divisional profits or losses from the CSA activities over the duration of the CSA activity, attributable to the external contributions. The income method requires the identification and projection of the relevant income streams, the allocation of costs and routine returns to determine residual profits attributable to the contributed intangibles, and the discounting of those residual profits to present value using an appropriate discount rate that reflects the riskiness of the projected cash flows.

The regulations also describe several other methods for valuing PCTs, including the acquisition price method (Treas. Reg. § 1.482-7(g)(5)), the market capitalization method (Treas. Reg. § 1.482-7(g)(6)), and the residual profit split method (Treas. Reg. § 1.482-7(g)(7)). The selection among these methods is governed by the best method rule of Treas. Reg. § 1.482-1(c), which requires application of the method that provides the most reliable measure of an arm's-length result under the specific facts and circumstances.

III.C. Transfer Pricing Methods for Intangible Property Under Treas. Reg. § 1.482-4

Treasury Regulation § 1.482-4 provides methods for determining the arm's-length amount charged in a controlled transaction involving the transfer of intangible property. The specified methods include the comparable uncontrolled transaction ("CUT") method (Treas. Reg. § 1.482-4(c)), the comparable profits method ("CPM") (as applied under Treas. Reg. § 1.482-5), and unspecified methods that may be applied where the specified methods do not provide a reliable measure of an arm's-length result. Treas. Reg. § 1.482-4(d).

While the primary focus of this report is the PCT valuation under Treas. Reg. § 1.482-7(g)(4), the provisions of Treas. Reg. § 1.482-4 are relevant to the related royalty arrangement for legacy IP. Specifically, certain legacy IP that was not included in the CSA is licensed by PPC to PBI under a separate intercompany license agreement at a royalty rate of 4.5% of net sales. WVG's CUT analysis of this royalty rate, discussed in Section XI below, is governed by the principles of Treas. Reg. § 1.482-4(c) and provides additional confirmation of the arm's-length nature of the PPC-PBI transfer pricing framework.

III.D. IRC § 367(d) Considerations

Section 367(d) of the Internal Revenue Code addresses certain transfers of intangible property by a United States person to a foreign corporation in an exchange described in Section 332, 351, 354, 356, or 361. Under Section 367(d), the U.S. transferor is treated as having transferred the intangible property in exchange for payments contingent on the productivity, use, or disposition of such property, and must include in income for each taxable year amounts that would be commensurate with the income attributable to the transferred intangible.

The potential application of Section 367(d) to the PPC-PBI CSA arrangement is a legal question that falls within the province of C&H as counsel. For purposes of this report, WVG notes that the IRS examination has focused its challenge on the PCT valuation under the Section 482 / CSA framework rather than seeking to recharacterize the CSA as an outbound IP transfer under Section 367(d). WVG's analysis is accordingly framed within the Section 482 / Treas. Reg. § 1.482-7 framework. To the extent the IRS were to raise a Section 367(d) recharacterization argument, the underlying economic analysis of the value of the contributed IP would remain substantially the same, although the legal consequences and the form of the adjustment might differ. WVG defers to C&H on all legal aspects of this issue.

III.E. OECD Transfer Pricing Guidelines

While the OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations do not have the force of law in the United States, they are recognized as persuasive authority in transfer pricing matters and provide a useful framework for economic analysis. See, e.g., Xilinx, Inc. v. Commissioner, 125 T.C. 37, 62 (2005) (noting that the OECD Guidelines are "an important source of interpretive guidance"), aff'd and rev'd on other grounds, 598 F.3d 1191 (9th Cir. 2010).

The OECD Transfer Pricing Guidelines, as revised in 2017 and updated in 2022, address the treatment of intangibles in Chapter VI and the treatment of cost contribution arrangements in Chapter VIII. Chapter VI introduces the concept of the "DEMPE" framework, which holds that the allocation of returns from intangibles should be based on which entity or entities perform the development, enhancement, maintenance, protection, and exploitation functions with respect to the intangible, assuming and managing the associated risks with appropriate financial capacity. The DEMPE framework is relevant to the PCT valuation insofar as it underscores the importance of analyzing PBI's functional profile — its personnel, decision-making authority, risk-bearing capacity, and operational activities — in determining the arm's-length allocation of intangible-related returns.

Chapter VIII of the OECD Guidelines addresses cost contribution arrangements, including the requirement that buy-in payments for pre-existing contributions be valued at arm's length. The principles articulated in Chapter VIII are broadly consistent with the U.S. regulatory framework under Treas. Reg. § 1.482-7, and WVG's analysis is consistent with both frameworks.

IV. DESCRIPTION OF THE PLATFORM CONTRIBUTION TRANSACTION

IV.A. CSA Structure and PCT Context

The CSA between PPC and PBI was executed effective July 1, 2012. Under the CSA, PPC and PBI agreed to share the costs and risks of developing and enhancing PPC's pharmaceutical intellectual property portfolio in proportion to their respective shares of the reasonably anticipated benefits from exploiting that portfolio in their assigned territories. PPC retained the exclusive right to develop and exploit the CSA intellectual property in the Americas, while PBI acquired the exclusive right to develop and exploit the CSA intellectual property outside the Americas (the "non-Americas" territory, encompassing EMEA and APAC markets).

In consideration for PBI's acquisition of rights in PPC's pre-existing IP portfolio as of the CSA date, PBI made two categories of payments:

(a) PCT Payment. A lump-sum platform contribution transaction payment of $312,000,000, payable on July 1, 2012, representing the arm's-length value of PBI's buy-in to PPC's pre-existing intellectual property portfolio as of that date. This payment was calculated using the income method / DCF approach as set forth in the contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP.

(b) Ongoing Cost-Sharing Payments. Ongoing payments by PBI of its proportionate share of the qualified research and development costs incurred under the CSA, calculated annually based on PBI's share of the reasonably anticipated benefits from the CSA activity. PBI's share of RAB, and thus its share of annual qualified R&D costs, was determined each year based on projected revenue allocations between the Americas and non-Americas territories.

The PCT payment is the subject of the IRS's challenge and is the focus of this report. The ongoing cost-sharing payments are addressed only to the extent relevant to the overall consistency analysis.

IV.B. Pre-Existing IP Portfolio Contributed

As of the PCT date of July 1, 2012, PPC's pre-existing IP portfolio included pharmaceutical compounds at various stages of development and commercialization. The portfolio represented the accumulated results of PPC's research and development investment over more than a decade, including extensive pre-clinical and clinical work, regulatory filings, and early-stage commercial activities. The key products in the portfolio at the contribution date are described below.

Veritaxol (Oncology). Veritaxol is a first-in-class small-molecule inhibitor targeting a novel oncogenic pathway, initially developed for the treatment of advanced non-small cell lung cancer ("NSCLC") and subsequently approved for additional oncology indications. At the PCT date, Veritaxol had received U.S. FDA approval for its initial indication (first-line treatment of EGFR-mutation-positive NSCLC) in October 2011 and was in the early stages of commercialization in the United States. Regulatory filings in the European Union, Japan, and other non-Americas markets were either pending or in preparation. As of July 1, 2012, Veritaxol had generated approximately $180 million in cumulative U.S. net sales since launch and was projected to achieve significant growth as additional markets were accessed and additional indications were pursued. By 2020, Veritaxol had become PPC's blockbuster product, generating global net sales of $3.12 billion, of which $1.34 billion (approximately 43%) was attributable to non-Americas markets.

Imvara (Immunology). Imvara is a biologic agent developed for the treatment of moderate-to-severe autoimmune conditions, including rheumatoid arthritis and psoriatic arthritis. At the PCT date, Imvara was in late-stage development, with a pivotal Phase III clinical trial underway and top-line data expected in the second half of 2013. The Phase III program involved approximately 2,400 patients across multiple clinical sites globally. At the contribution date, Imvara's future commercial success was uncertain, as the Phase III trial had not yet read out and the compound faced competition from established biologic therapies. Accordingly, probability-adjusted revenue projections were applied in the original PCT valuation, reflecting the clinical and regulatory risk inherent in a Phase III compound. Imvara subsequently received FDA approval in 2015 and achieved global net sales of $1.87 billion by 2020, of which $790 million (approximately 42%) was attributable to non-Americas markets.

Cerulon (Rare Disease). Cerulon is an enzyme replacement therapy developed for the treatment of a specific lysosomal storage disorder, a rare genetic condition affecting an estimated 5,000 to 8,000 patients globally. At the PCT date, Cerulon was in early-stage development, having completed preclinical studies and initial Phase I/II clinical evaluation. The compound had received orphan drug designation from the FDA but was several years away from potential regulatory approval. The probability of clinical and regulatory success for a compound at this stage of development was substantially lower than for Veritaxol or Imvara, and the revenue projections for Cerulon in the original PCT valuation reflected significant probability discounts. Cerulon received regulatory approvals in the United States, European Union, and Japan between 2016 and 2018, and achieved global net sales of $620 million by 2020, of which $280 million (approximately 45%) was attributable to non-Americas markets.

Other Pipeline Compounds. The contributed IP portfolio also included several additional compounds in pre-clinical and early clinical stages of development. These compounds were individually smaller in projected value and carried higher development risk. In the aggregate, they contributed modestly to the overall PCT valuation after probability weighting. WVG's analysis includes these compounds in the revenue projections and DCF model, consistent with the approach taken in the original contemporaneous valuation.

In addition to the compounds included in the CSA, certain legacy IP was licensed separately by PPC to PBI under an intercompany license agreement at a royalty rate of 4.5% of net sales. The legacy IP included certain older branded products that were already commercially established at the time of PBI's incorporation and were not included in the CSA cost-sharing framework. The legacy IP royalty arrangement is not part of the PCT valuation but is contextually relevant and is addressed in WVG's separate CUT analysis, cross-referenced in Section XI of this report.

IV.C. Cost-Sharing Ratios

Under the CSA, PBI's annual share of qualified R&D costs is determined based on its share of the reasonably anticipated benefits from the CSA activity, measured by projected revenue allocations between PPC (Americas) and PBI (non-Americas). As PBI's non-Americas commercial operations expanded and revenues grew, PBI's RAB share — and thus its cost-sharing percentage — increased over time. The following table summarizes PBI's cost-sharing percentages and payments for the examination years:

The IRS's proposed adjustments for the 2017–2020 tax years include, among other things, a recharacterization of PBI's cost-sharing ratios based on the IRS's assertion that the PCT was undervalued by $540 million. The IRS contends that if the PCT had been valued at $852 million, the cost-sharing ratios should have been recalibrated to reflect a different allocation of residual profits between PPC and PBI. WVG's analysis demonstrates that the cost-sharing ratios as applied are consistent with an arm's-length PCT valuation of $312 million and are not subject to adjustment.

IV.D. PBI's Functional Profile

A key element of both the PCT valuation and the broader transfer pricing analysis is the functional profile of PBI — the functions it performs, the assets it employs, and the risks it assumes in the non-Americas territories. WVG's analysis of PBI's functional profile is based on a review of PBI's organizational structure, headcount data, board minutes, regulatory expenditure records, and other operational documentation, as well as discussions with C&H and PPC personnel.

Personnel and Operations. PBI maintained its principal office at Sandyford Business Park, Dublin, occupying approximately 18,000 square feet of office space. PBI's headcount grew from 52 employees at inception (2012) to 185 employees by 2020. PBI's workforce included professionals in regulatory affairs, medical affairs, commercial strategy, supply chain management, finance, and legal functions. Key decision-makers within PBI included the Managing Director, the Vice President of Commercial Operations, the Vice President of Regulatory Affairs, and the Vice President of Medical Affairs, all of whom were based in Dublin and reported to PBI's board of directors.

Decision-Making Authority. PBI exercised meaningful decision-making authority over the commercialization of CSA products in the non-Americas territory. Specifically, PBI was responsible for pricing decisions, market entry strategy, selection and management of distribution partners, regulatory submission strategy and timing, and medical affairs activities across 68 country markets. PBI's board of directors held 42 meetings in Dublin over the 2017–2020 period, at which key commercial and operational decisions were discussed and approved. Board meeting minutes reviewed by WVG confirm that PBI's board was actively engaged in strategic oversight and was not merely ratifying decisions made by PPC in the United States.

Risk-Bearing. PBI bore the commercial and market risk associated with the non-Americas territory. This included the risk of adverse regulatory outcomes in non-U.S. jurisdictions, pricing and reimbursement risk in markets with government-controlled pricing regimes (including the EU, Japan, and other APAC markets), currency risk (PBI operated in over 20 functional currencies), and competition risk from established and generic competitors.

Regulatory Expenditures. PBI incurred cumulative regulatory expenditures of €47.2 million across non-Americas markets during the 2017–2020 period. These expenditures related to regulatory filings, post-marketing commitments, pharmacovigilance activities, and interactions with regulatory authorities in the EU (European Medicines Agency), Japan (PMDA), and other non-Americas jurisdictions.

Banking and Treasury. PBI maintained independent banking operations with Glenmore Bank Ireland plc, including operating accounts, hedging facilities, and cash management arrangements. PBI managed its own treasury function with respect to working capital, intercompany settlements, and foreign exchange hedging.

Contract Manufacturing. PBI contracted with Penterra Manufacturing Ireland Ltd. ("PMI") for the contract manufacturing of pharmaceutical products for non-Americas markets. PMI is an Irish private limited company (CRO Number 512347) located at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland, with approximately 620 employees engaged in pharmaceutical manufacturing and quality assurance operations. PBI compensated PMI at cost plus an 8% markup, consistent with arm's-length benchmarking of contract manufacturing arrangements in the pharmaceutical industry.

PBI's functional profile is consistent with that of a full-fledged commercial principal and IP-holding entity, rather than a passive holding company or conduit. This characterization is relevant to both the PCT valuation — insofar as PBI's ability to generate value from the contributed IP supports the projected revenue and profit levels — and the broader transfer pricing analysis under the DEMPE framework. WVG's conclusions regarding PBI's functional profile are further supported by the CPM/TNMM analysis discussed in Section XI.

V. VALUATION METHODOLOGY: INCOME METHOD / DCF APPROACH

V.A. Selection of the Income Method

WVG selected the income method under Treas. Reg. § 1.482-7(g)(4) as the best method for determining the arm's-length value of the PCT payment. This selection is consistent with the best method rule of Treas. Reg. § 1.482-1(c), which requires application of the method that provides the most reliable measure of an arm's-length result under the specific facts and circumstances.

The income method is appropriate for valuing the PCT in this case because the pre-existing intangibles contributed to the CSA generate identifiable income streams in the non-Americas territory that can be projected and discounted to present value. The contributed IP portfolio consists of pharmaceutical compounds with quantifiable revenue potential, for which market size estimates, clinical development probabilities, pricing assumptions, and competitive dynamics can be analyzed on a product-by-product basis. The income method allows for the direct quantification of the economic value of these income streams to PBI as the non-Americas participant, which is the conceptual framework prescribed by the regulations for PCT valuation.

WVG considered the alternative methods specified in the regulations and determined that they do not provide a more reliable measure of the arm's-length PCT value in this case, for the following reasons:

Acquisition Price Method (Treas. Reg. § 1.482-7(g)(5)). The acquisition price method determines the PCT value by reference to the price paid in an arm's-length acquisition of comparable intangible property. WVG was unable to identify any arm's-length acquisitions of pharmaceutical IP portfolios that were sufficiently comparable to the PPC contributed portfolio in terms of the therapeutic areas, development stages, geographic scope, and risk profile of the compounds involved. While pharmaceutical licensing and acquisition transactions are common, the unique composition of the contributed portfolio — including a mix of approved, Phase III, and early-stage oncology, immunology, and rare-disease compounds with specific geographic rights — precluded the identification of transactions with adequate comparability. The acquisition price method was therefore rejected as insufficiently reliable.

Market Capitalization Method (Treas. Reg. § 1.482-7(g)(6)). The market capitalization method derives the PCT value from the market capitalization of the entity to which the intangibles are contributed, adjusted for other assets and liabilities. This method is most reliable where the recipient entity is publicly traded and its market capitalization provides a transparent measure of the value of its intangible assets. PBI was not publicly traded at any relevant time, and its market value was not independently observable. While it might theoretically be possible to impute a market value for PBI based on the value of PPC's overall market capitalization and the relative value of the non-Americas business, such an approach would involve multiple layers of estimation and assumption that would reduce its reliability relative to the income method. The market capitalization method was therefore rejected.

Residual Profit Split Method (Treas. Reg. § 1.482-7(g)(7)). The residual profit split method allocates combined profits between the CSA participants based on the relative values of their respective contributions. WVG considered the residual profit split method as a potential cross-check on the income method results. While the residual profit split method can provide useful information in certain circumstances, WVG concluded that the income method provides a more reliable primary result in this case because it directly quantifies the present value of the income streams attributable to the contributed IP in the non-Americas territory, without the need for the additional allocation step required under the residual profit split method. WVG has, however, confirmed that the results of the income method are directionally consistent with a residual profit split analysis, which provides additional confidence in the reliability of the income method result.

For these reasons, WVG concluded that the income method / DCF approach is the best method for the PCT valuation and applied this method as the primary basis for its analysis.

V.B. DCF Framework

Under the income method, the PCT value equals the present value of the expected incremental cash flows attributable to the pre-existing IP from the non-Americas territory, discounted over the useful life of the contributed intangibles at an appropriate risk-adjusted rate. The general DCF framework is expressed as follows:

PCT Value = Σ [Expected Divisional Profits_t / (1 + WACC)^t] for t = 1 to n

Where:

• Expected Divisional Profits_t represents the residual divisional profits attributable to the pre-existing IP in the non-Americas territory in year t, after deducting routine returns on PBI's tangible assets and workforce contributions;

• WACC represents the weighted average cost of capital, determined based on the risk profile of the projected cash flows;

• n represents the number of years in the projection period (including any terminal value period); and

• t represents the year index, with t = 1 corresponding to the first year after the PCT date (July 1, 2012).

The key inputs to the DCF model are: (1) revenue projections for the non-Americas territory, disaggregated by product and adjusted for clinical success probabilities; (2) cost structure assumptions, including cost of goods sold, operating expenses, and routine returns; (3) terminal value and useful life assumptions; and (4) the discount rate (WACC). Each of these inputs is discussed in detail in Sections VI through VIII of this report.

The divisional profit concept is central to the income method. Divisional profit is defined as the total profit generated by PBI from the exploitation of the contributed IP in the non-Americas territory, less routine returns attributable to PBI's tangible assets (e.g., working capital, fixed assets) and routine functional contributions (e.g., the returns attributable to PBI's distribution, regulatory, and administrative functions). The residual divisional profit, after deducting these routine returns, represents the profit attributable to the contributed intangible property — that is, the value for which the PCT payment is the arm's-length compensation.

V.C. Projection Period and Useful Life

WVG employed a 15-year explicit forecast period, spanning from the PCT date (July 1, 2012) through June 30, 2027, reflecting the estimated remaining commercial life of the contributed compounds. This projection horizon was determined based on an analysis of the following factors:

Average Remaining Patent Life. As of July 1, 2012, the key compounds in the contributed portfolio had remaining patent lives ranging from approximately 8 years (for certain formulation patents on Veritaxol) to approximately 18 years (for composition-of-matter patents on Cerulon and certain pipeline compounds). The weighted average remaining patent life, considering the relative value of each compound in the portfolio, was approximately 14 years. WVG's 15-year explicit forecast period encompasses this weighted average patent life with a modest extension to account for potential patent term extensions and pediatric exclusivity periods available under U.S. and EU law.

Historical Pharmaceutical Product Lifecycles. Industry data on pharmaceutical product lifecycles indicates that branded pharmaceutical products typically experience peak revenues approximately 5 to 10 years after initial launch, followed by a gradual decline as patents expire and generic or biosimilar competition enters the market. The 15-year projection period is consistent with this lifecycle pattern for the contributed portfolio, which included products at various stages from early commercialization to early-stage development.

Terminal Value. Beyond the 15-year explicit forecast period, WVG applied a declining cash flow model to capture the residual value of the contributed IP beyond Year 15. This terminal value model assumes that revenues decline at a rate of approximately 15% to 25% per year after patent expiration, reflecting the impact of generic competition, biosimilar entry, and lifecycle decline. The terminal value is discounted to present value at the same WACC (9.8%) applied to the explicit forecast period cash flows. The declining cash flow model is more conservative than a perpetuity-based terminal value approach, which WVG considered inappropriate given the finite patent-protected life of pharmaceutical intangibles.

The 15-year projection period and declining-cash-flow terminal value methodology are consistent with industry valuation practices for pharmaceutical intangible assets, as reflected in published literature and WVG's experience in pharmaceutical IP valuations.

VI. REVENUE PROJECTIONS

VI.A. Revenue Forecasting Methodology

A critical input to the DCF model is the projection of revenues attributable to the contributed IP in the non-Americas territory over the 15-year forecast period. WVG's revenue projections were prepared as of the PCT date (July 1, 2012), based on information reasonably available at that time. This as-of-date framework is required by the regulations and is essential to the integrity of the valuation, as the arm's-length value of the PCT must be determined based on the information and expectations that would have been available to hypothetical arm's-length parties as of the transaction date, not on the basis of subsequent actual outcomes. See Treas. Reg. § 1.482-7(g)(4)(vi)(F) (the financial projections used in the income method "must be the most reliable projections . . . from the perspective of the date of the PCT").

WVG's revenue forecasting methodology involved the following steps:

1. Product-by-Product Analysis. Revenue projections were developed on a product-by-product basis for each compound included in the CSA portfolio, reflecting the specific clinical development status, regulatory pathway, competitive landscape, and market potential of each compound as of July 1, 2012.

2. Clinical Development Probability Adjustments. For compounds that were not yet approved as of the PCT date (i.e., Imvara, Cerulon, and other pipeline compounds), revenue projections were adjusted by probability-of-success factors reflecting the likelihood that each compound would successfully complete clinical development and obtain regulatory approval. These probability factors were based on published industry data regarding historical clinical trial success rates by development phase and therapeutic area, sourced from databases such as Beaumont Systems and published studies by DiMasi et al. (2010), Thomas et al. (2016), and others.

3. Market Size and Penetration Estimates. For each compound, WVG estimated the total addressable market in the non-Americas territory based on epidemiological data, current treatment paradigms, and pricing and reimbursement dynamics in key non-Americas markets (EU5, Japan, China, Brazil, and other significant markets). Market penetration rates were estimated based on the compound's projected efficacy and safety profile, competitive positioning, and expected launch timing in each market.

4. Pricing Assumptions. Pricing assumptions reflected the expected ex-manufacturer net prices in each major non-Americas market, taking into account government-controlled pricing and reimbursement systems, reference pricing mechanisms, and competitive pricing dynamics. Non-Americas prices were generally assumed to be lower than U.S. prices, consistent with observed international pharmaceutical pricing differentials.

5. Launch Timing. Projected launch dates in non-Americas markets were based on the expected timelines for regulatory submissions and approvals in the EU (EMA), Japan (PMDA), and other key markets, taking into account the typical lag between U.S. and non-U.S. approvals for pharmaceutical products.

6. Competitive Landscape Analysis. Revenue projections incorporated an assessment of the competitive landscape as of July 1, 2012, including existing and anticipated competitive products, potential generic or biosimilar entry upon patent expiration, and the expected evolution of treatment guidelines.

VI.B. Product-Level Revenue Projections

Veritaxol (Oncology). At the PCT date, Veritaxol had been approved by the FDA for approximately eight months and was in the early stages of U.S. commercialization. EU regulatory filings were in progress, with EMA approval anticipated in 2013. Japanese regulatory filings were expected to follow, with PMDA approval anticipated in 2014. Veritaxol's novel mechanism of action and promising clinical data positioned it as a potential best-in-class agent for EGFR-mutation-positive NSCLC, but the product's commercial trajectory was still uncertain given the early stage of commercialization and the presence of several established competitors in the NSCLC market.

WVG's as-of-date revenue projections for Veritaxol in the non-Americas territory assumed:

• EU launch in mid-2013, with initial market penetration building gradually as reimbursement approvals were obtained in individual EU member states;

• Japanese launch in early 2015, following PMDA approval;

• Expansion to additional APAC markets (China, South Korea, Australia) and other EMEA markets over the 2015–2018 period;

• Peak non-Americas net sales reaching approximately $1.0 billion to $1.4 billion, achievable by approximately Year 8 to Year 10 of the projection period (2020–2022);

• Subsequent decline following patent expiration, with generic entry assumed beginning in the 2023–2025 timeframe depending on the specific market and applicable patent protection.

Comparison to Actual Performance. By 2020, Veritaxol had achieved non-Americas net sales of $1.34 billion ($3.12 billion global). This actual result was within the range of WVG's as-of-date projections, though at the upper end, reflecting the product's strong commercial execution and the successful expansion of its label to additional oncology indications (including second-line NSCLC and adjuvant treatment) that were not fully anticipated at the PCT date. WVG notes that while the actual outcome is a useful reference point, it does not determine the appropriate as-of-date valuation; the valuation must be based on what was reasonably anticipated as of July 1, 2012.

Imvara (Immunology). At the PCT date, Imvara was in late-stage development, with a pivotal Phase III clinical trial underway. The Phase III trial was a large, multi-center, randomized controlled trial evaluating Imvara versus placebo in patients with moderate-to-severe rheumatoid arthritis who had experienced inadequate response to methotrexate. Enrollment had been completed, and top-line data were expected in the second half of 2013. While the preclinical and Phase I/II data for Imvara were encouraging, the outcome of the Phase III trial was uncertain as of the PCT date, and there was a meaningful risk that the trial would not meet its primary endpoint or would produce safety signals that could delay or prevent regulatory approval.

WVG's as-of-date revenue projections for Imvara applied a clinical success probability factor of approximately 55% to 65%, reflecting the historical probability of success for biologic compounds in Phase III clinical trials in the immunology therapeutic area. This probability factor was applied to the unadjusted (pre-probability) revenue projections to produce probability-weighted revenue estimates.

WVG's projections assumed:

• Probability-adjusted U.S. approval in 2015, with EU and Japanese approvals following approximately 12 to 18 months later;

• Non-Americas launches commencing in 2016 (EU) and 2017 (Japan);

• Peak probability-adjusted non-Americas net sales reaching approximately $550 million to $750 million by approximately Year 10 to Year 12 of the projection period;

• Revenue decline following loss of exclusivity, with biosimilar entry assumed beginning approximately 12 to 14 years after initial launch.

Comparison to Actual Performance. Imvara successfully completed its Phase III trial, received FDA approval in 2015, and achieved non-Americas net sales of $790 million by 2020 ($1.87 billion global). The actual outcome exceeded the probability-weighted projections, as would be expected when a clinical-stage compound is ultimately approved and commercialized. The unadjusted (pre-probability) revenue projections were generally consistent with the actual outcome, confirming that the underlying market assumptions were reasonable.

Cerulon (Rare Disease)

At the PCT date, Cerulon was in early-stage clinical development, having completed initial Phase I/II studies in a small number of patients. The compound had received orphan drug designation from the FDA, which provided certain regulatory and commercial advantages (including market exclusivity and potential fast-track review), but was several years away from potential regulatory approval. The clinical development pathway for Cerulon involved additional Phase II and Phase III studies, which were expected to take approximately four to six years to complete. The probability of a compound at this stage successfully reaching regulatory approval was significantly lower than for a compound already in Phase III.

WVG applied a cumulative clinical success probability factor of approximately 20% to 30% to the Cerulon revenue projections, reflecting the historical probability of success for enzyme replacement therapies transitioning from Phase I/II through regulatory approval. This probability weighting substantially reduced the contribution of Cerulon to the overall PCT valuation, which is appropriate given the high level of development risk inherent in an early-stage compound.

WVG's probability-weighted projections for Cerulon assumed:

• Probability-adjusted first regulatory approval in the 2017–2019 timeframe;

• Non-Americas launches commencing approximately 12 to 24 months after initial approval;

• Peak probability-adjusted non-Americas net sales reaching approximately $80 million to $150 million;

• Revenue persistence over a longer period than the oncology and immunology compounds, reflecting the limited competition and orphan drug exclusivity typically associated with rare-disease therapeutics.

Comparison to Actual Performance. Cerulon received regulatory approvals in the United States, European Union, and Japan between 2016 and 2018 and achieved non-Americas net sales of $280 million by 2020 ($620 million global). As with Imvara, the actual outcome exceeded the probability-weighted projections, which is the expected result when a high-risk compound is ultimately successful.

Other Pipeline Compounds

The contributed IP portfolio included several additional compounds in pre-clinical and early clinical stages of development. Given the very early stage of these compounds, WVG applied cumulative clinical success probability factors of approximately 5% to 15%, depending on the specific compound's development stage and therapeutic area. In aggregate, these compounds contributed modestly to the overall PCT valuation after probability weighting. WVG's revenue projections for these compounds are set forth in the product-level revenue projection summary in Exhibit 8.

VI.C. Comparison of WVG Projections to IRS Projections

The IRS economist, Dr. Alan Washburne, developed revenue projections as part of the IRS's income-method valuation that differ materially from WVG's projections. WVG has identified the following principal areas of disagreement:

Higher Revenue Growth Assumptions. Dr. Washburne's projections assume higher revenue growth rates for the contributed compounds in the non-Americas territory, particularly in the early years of the projection period. In several cases, the IRS's assumed growth rates exceed the upper bound of the range that WVG considers reasonable based on information available as of July 1, 2012.

Lower Risk Adjustments for Clinical-Stage Compounds. Dr. Washburne applied materially lower probability-of-success discounts to the revenue projections for compounds in clinical development as of the PCT date. For Imvara (Phase III), Dr. Washburne applied a clinical success probability of approximately 80%, compared to WVG's range of 55% to 65%. For Cerulon (early-stage), Dr. Washburne applied a cumulative probability of approximately 45%, compared to WVG's range of 20% to 30%. These higher probability assumptions have the effect of significantly increasing the projected revenue contribution of clinical-stage compounds, thereby inflating the PCT value.

Inadequate Accounting for Competitive and Generic Entry Risks. Dr. Washburne's projections do not adequately account for the risk of competitive entry from established competitors, new entrants, or generic/biosimilar products following patent expiration. The IRS projections assume longer periods of peak revenue and more gradual post-patent revenue decline than WVG considers supportable based on pharmaceutical indu

PRIVILEGED AND CONFIDENTIAL PREPARED AT THE DIRECTION OF COUNSEL UNDER KOVEL ARRANGEMENT ATTORNEY-CLIENT PRIVILEGE AND WORK PRODUCT DOCTRINE APPLY
Platform Contribution Transaction Valuation Analysis
Income Method / Discounted Cash Flow Approach
Penterra Pharmaceuticals Corp.
Cost-Sharing Arrangement with Penterra Biopharma International DAC
Prepared by:
Whitmore Valuation Group LLC 200 Ashbury Asset Advisors, Suite 700 Boston, MA 02109
Lead Economist: Dr. Helena Vasquez, Ph.D. Managing Director
Supporting Economist: Dr. Rohan Chakrabarti, Ph.D. Senior Director
Prepared at the Direction of Counsel:
Calderwood & Harkness LLP 1735 Market Street, Suite 3100 Philadelphia, PA 19103
Leonard Cross, Partner (Responsible Attorney) Garrett Simmons, Associate (Lead Associate)
December 2022
C&H Matter Number 1018-00009-KV
CONFIDENTIAL — PRIVILEGED AND CONFIDENTIAL Prepared at the Direction of Counsel Under Kovel Arrangement Attorney-Client Privilege and Work Product Doctrine Apply This document and its contents are protected from disclosure to third parties under the attorney-client privilege and the work product doctrine.
I. EXECUTIVE SUMMARY
Whitmore Valuation Group LLC ("WVG") was retained by Calderwood & Harkness LLP ("C&H"), outside tax counsel to Penterra Pharmaceuticals Corp. ("PPC"), under a Kovel arrangement (Kovel letter dated June 20, 2022, reference C&H Matter No. 1018-00009-KV), to perform an independent economic analysis of the platform contribution transaction ("PCT") payment made by Penterra Biopharma International DAC ("PBI") to PPC on July 1, 2012, in connection with a qualified cost-sharing arrangement ("CSA") entered into between PPC and PBI on that same date. This report sets forth WVG's analysis, methodology, findings, and conclusions.
The PCT payment of $312,000,000 represented PBI's buy-in to PPC's pre-existing pharmaceutical intellectual property portfolio, which consisted primarily of clinical-stage and approved oncology compounds, in exchange for PBI's right to develop and exploit that intellectual property outside the Americas (defined as North America, Central America, South America, and the Caribbean, collectively the "Americas"). The IP portfolio at the PCT date included, among other compounds, Veritaxol (an approved oncology product in early commercialization), Imvara (an immunology compound in late-stage development), and Cerulon (a rare-disease compound in early-stage development), as well as several smaller pipeline assets. The PCT payment was calculated at the time of the transaction using the income method under a discounted cash flow ("DCF") approach, as contemplated by Treasury Regulation § 1.482-7(g)(4), and was documented in contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP.
The Internal Revenue Service ("IRS"), through its Large Business & International ("LB&I") Division, Northeast Transfer Pricing Practice (Exam Team LB&I-NE-TP-2022-00641), has challenged the PCT valuation in connection with the examination of PPC's consolidated federal income tax returns for the tax years ending December 31, 2017, 2018, 2019, and 2020. While the tax year in which the PCT payment was made (2012) is outside the examination period, the IRS has used the asserted PCT undervaluation as a basis for recharacterizing PBI's ongoing cost-sharing ratios and related royalty rates for the 2017–2020 tax years. Specifically, the IRS asserts that the $312,000,000 PCT payment undervalued the pre-existing IP by approximately $540,000,000, proposing that the PCT should have been valued at $852,000,000 using an income method with a lower weighted average cost of capital ("WACC") of 7.2% and different revenue projections. This asserted undervaluation forms part of the basis for $380,400,000 in net proposed adjustments to PPC's taxable income under Internal Revenue Code ("IRC") § 482, as set forth in the Notice of Proposed Adjustment ("NOPA") dated October 12, 2023.
WVG performed an independent analysis of the PCT valuation using the income method / DCF approach prescribed by Treas. Reg. § 1.482-7(g)(4). WVG's analysis is based on revenue projections prepared as of July 1, 2012, reflecting information reasonably available at that date, a detailed cost structure analysis consistent with PBI's actual and projected operating profile, and a risk-adjusted WACC of 9.8%, derived from a rigorous build-up methodology incorporating the Capital Asset Pricing Model ("CAPM"), an industry-specific equity risk premium, beta derived from comparable specialty pharmaceutical and biotechnology companies, and appropriate size and company-specific risk premiums reflecting PBI's status as a newly incorporated entity with limited personnel and no independent operating history.
Based on WVG's analysis, the arm's-length range for the PCT payment is $278,000,000 to $361,000,000. This range was established by varying key inputs — including the discount rate, revenue growth assumptions, clinical success probability adjustments, and terminal value assumptions — within reasonable bounds supported by market data, industry benchmarks, and economic analysis. The $312,000,000 PCT payment falls squarely within this arm's-length range, at approximately the 60th percentile, confirming that the payment satisfies the arm's-length standard under IRC § 482 and Treas. Reg. § 1.482-7(g)(4).
WVG's principal conclusions are as follows:
1. The $312,000,000 PCT payment is within the arm's-length range of $278,000,000 to $361,000,000 and satisfies the arm's-length standard under IRC § 482 and Treas. Reg. § 1.482-7.
2. The IRS's proposed PCT valuation of $852,000,000, based on a WACC of 7.2% and inflated revenue projections, is not within the arm's-length range and is not supportable under the best method rule set forth in Treas. Reg. § 1.482-1(c).
3. The $540,000,000 delta asserted by the IRS is attributable primarily to: (a) an inappropriately low discount rate that fails to account for pharmaceutical-specific and company-specific risk factors, and (b) revenue projections that incorporate impermissible hindsight by effectively embedding knowledge of actual product successes that was not available at the PCT date.
4. The PCT valuation is internally consistent with WVG's parallel analyses of the legacy IP royalty rate (4.5%) under the comparable uncontrolled transaction ("CUT") method and PBI's operating margins under the comparable profits method ("CPM") / transactional net margin method ("TNMM"), further confirming the arm's-length character of the PPC-PBI transfer pricing framework.
II. ENGAGEMENT AND SCOPE
II.A. Engagement Background
Penterra Pharmaceuticals Corp. PPC is a corporation organized under the laws of the State of Delaware, publicly traded on the Nasdaq Global Select Market under the ticker symbol "PPCA," with its principal executive offices located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceutical and biotechnology company focused on the discovery, development, manufacturing, and commercialization of innovative therapeutics in three principal therapeutic areas: oncology, immunology, and rare-disease therapeutics. For the fiscal year ended December 31, 2020, PPC reported consolidated annual revenue of approximately $6.82 billion and pre-tax income of approximately $1.47 billion. As of the same date, PPC employed approximately 14,500 individuals globally, including approximately 3,200 in research and development functions, 4,800 in manufacturing and supply chain operations, and 6,500 in commercial, medical affairs, regulatory, and administrative roles.
PPC's product portfolio consists of more than 25 marketed products across the oncology, immunology, and rare-disease segments, with a pipeline of approximately 40 compounds in various stages of clinical and pre-clinical development. PPC's lead product, Veritaxol, is a first-in-class oncology compound that achieved global net sales of $3.12 billion in fiscal year 2020, making it one of the top-selling oncology products globally. Imvara, an immunology product that received U.S. Food and Drug Administration approval in 2015, generated global net sales of $1.87 billion in fiscal year 2020. Cerulon, a rare-disease therapeutic that received orphan drug designation and regulatory approval in key markets between 2016 and 2018, generated global net sales of $620 million in fiscal year 2020.
Penterra Biopharma International DAC. PBI is a Designated Activity Company organized under the laws of Ireland, registered with the Companies Registration Office of Ireland (CRO Number 511203), with its registered office located at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI was incorporated on March 15, 2012, approximately three and one-half months before the effective date of the CSA. PBI functions as the intellectual property holding company and commercial principal for the development and commercialization of PPC products outside the Americas. In this capacity, PBI manages contract manufacturing arrangements, distribution partnerships, regulatory filings, and pricing and market access strategies across approximately 68 country markets in the Europe, Middle East, and Africa ("EMEA") and Asia-Pacific ("APAC") regions.
PBI is a wholly-owned subsidiary of Penterra Holdings Luxembourg S.à r.l. ("PHL"), a société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg, with its registered office at 14, rue Aldringen, L-1118 Luxembourg (Registre de Commerce et des Sociétés, Luxembourg, No. B 168452). PHL is treated as a disregarded entity for U.S. federal income tax purposes. PHL is, in turn, 100% owned by PPC. Accordingly, PBI is an indirect, wholly-owned subsidiary of PPC, and PPC, PHL, and PBI are related parties within the meaning of IRC § 482 and the regulations thereunder.
IRS Examination. The IRS opened an examination of PPC's consolidated federal income tax returns for the tax years ending December 31, 2017, 2018, 2019, and 2020, by issuance of Letter 2205-A dated May 16, 2022. The examination is being conducted by the IRS LB&I Division, Northeast Transfer Pricing Practice, under Exam Team designation LB&I-NE-TP-2022-00641. As part of the examination, the IRS has challenged the valuation of the PCT payment and the related cost-sharing ratios applicable to the 2017–2020 tax years. The IRS's position, as set forth in the NOPA dated October 12, 2023, asserts that the $312,000,000 PCT payment undervalued the pre-existing IP by approximately $540,000,000, and that the correct PCT value under the income method is $852,000,000. The IRS has used this asserted undervaluation to recharacterize the cost-sharing ratios and to propose net adjustments totaling $380,400,000 to PPC's taxable income for the 2017–2020 tax years under IRC § 482.
Retention of WVG. WVG was retained by C&H, PPC's outside tax counsel, pursuant to a Kovel arrangement (Kovel letter dated June 20, 2022, reference 1018-00009-KV) to perform an independent economic analysis of the PCT payment and related transfer pricing issues. Under the Kovel arrangement, WVG's work product is prepared at the direction of counsel and is subject to the protections of the attorney-client privilege and the work product doctrine. See United States v. Kovel, 296 F.2d 918 (2d Cir. 1961).
II.B. Scope of Assignment
WVG was engaged to perform the following tasks:
1. PCT Valuation. Perform an independent valuation of the pre-existing intellectual property contributed to the CSA as of the PCT date (July 1, 2012) using the income method / DCF approach as prescribed by Treas. Reg. § 1.482-7(g)(4). This valuation encompasses the development and application of a DCF model incorporating product-level revenue projections, cost structure analysis, terminal value determination, and an appropriate risk-adjusted discount rate.
2. Arm's-Length Evaluation. Evaluate the appropriateness of the $312,000,000 PCT payment within the arm's-length standard, as articulated in Treas. Reg. § 1.482-1(b), by establishing an arm's-length range for the PCT value and determining whether the actual payment falls within that range.
3. Critique of IRS Valuation. Assess and critique the IRS economist's income-method valuation of $852,000,000, including the specific inputs employed by Dr. Alan Washburne, with particular focus on the IRS's discount rate (7.2% WACC), revenue projections, clinical success probability assumptions, and terminal value methodology.
4. Arm's-Length Range Determination. Determine an arm's-length range for the PCT value by performing sensitivity analyses across key valuation inputs, including the discount rate, revenue growth assumptions, and probability-weighting factors for clinical-stage compounds.
5. Consistency Analysis. Evaluate the internal consistency of the PCT valuation with WVG's parallel analyses of the legacy IP royalty rate (CUT method) and PBI's operating margins (CPM/TNMM), to confirm that the overall PPC-PBI transfer pricing framework reflects arm's-length results.
This report sets forth the results of WVG's analysis and constitutes WVG's work product prepared at the direction of C&H under the Kovel arrangement. This report is subject to attorney-client privilege and work product protection and is not intended for distribution to any party other than PPC, C&H, and their authorized representatives, except as may be required in connection with the IRS examination or related proceedings.
II.C. Information Sources and Materials Reviewed
In performing the analysis set forth in this report, WVG reviewed the following categories of documents and materials. A complete list of specific documents reviewed is set forth in Appendix A.
CSA and Related Agreements. The cost-sharing arrangement agreement between PPC and PBI, effective July 1, 2012, together with all subsequent amendments thereto. The CSA agreement defines the scope of the arrangement, the contributed IP, the cost-sharing methodology, the reasonably anticipated benefits ("RAB") calculations, and the PCT payment terms.
Original PCT Valuation. The contemporaneous PCT valuation report prepared by Crestfield & Associates LLP (Susan Lam, Transfer Pricing Partner; Martin Ogilvy, Engagement Partner), dated June 2012, which formed the basis for the $312,000,000 PCT payment. WVG reviewed this report in its entirety, including the underlying DCF model, revenue projections, discount rate analysis, and supporting workpapers.
Financial Statements and Tax Returns. PPC's consolidated financial statements (audited) and U.S. federal income tax returns (Forms 1120) for the tax years 2012 through 2020. PBI's Irish statutory financial statements and Irish corporate tax returns for the same period. These documents provided the basis for WVG's analysis of actual revenues, costs, profitability, and cost-sharing calculations.
Product-Level Revenue Data. Detailed product-level revenue data for Veritaxol, Imvara, Cerulon, and other CSA products, disaggregated by territory (Americas vs. non-Americas), for each year from 2012 through 2020. This data was provided by PPC's finance department and was reconciled to PPC's and PBI's financial statements.
R&D Cost Pool Data. Data relating to the qualified research and development costs included in the CSA cost pool for each of the examination years: $487.3 million (2017), $523.8 million (2018), $561.2 million (2019), and $598.4 million (2020).
PBI Operational Data. PBI headcount data (52 employees in 2012, growing to 185 employees in 2020), organizational charts, job descriptions for key personnel, PBI board of directors meeting minutes (42 meetings held in Dublin over the 2017–2020 period), and PBI regulatory expenditure records (€47.2 million cumulative for 2017–2020).
IRS Materials. The NOPA dated October 12, 2023, including the economic analysis prepared by Dr. Alan Washburne, IRS economist. WVG also reviewed correspondence between the IRS examination team and PPC/C&H relating to the PCT valuation and cost-sharing issues.
Industry Publications and Market Data. Pharmaceutical industry publications, market research reports (Kestrel Industries, Tidewater Holdings, Harborline Services Inc.), clinical trial databases (ClinicalTrials.gov), patent databases, and comparable pharmaceutical company financial data. WVG also utilized WVG's proprietary benchmarking databases, which contain financial and operational data for over 500 pharmaceutical, biotechnology, and life sciences companies globally.
Comparable Transaction Databases. WVG reviewed pharmaceutical licensing and collaboration transaction databases (Medtrack, Calderon Data Systems, RoyaltySource) to identify comparable uncontrolled transactions for benchmarking purposes in connection with the CUT analysis of the legacy IP royalty rate.
III. LEGAL AND REGULATORY FRAMEWORK
III.A. IRC § 482 and the Arm's-Length Standard
Section 482 of the Internal Revenue Code grants the Secretary of the Treasury broad authority to distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among two or more organizations, trades, or businesses that are owned or controlled directly or indirectly by the same interests, if the Secretary determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any such organizations, trades, or businesses. IRC § 482. The legislative purpose underlying Section 482 is to place commonly controlled taxpayers on a tax parity with uncontrolled taxpayers by determining the true taxable income of each controlled taxpayer. See Treas. Reg. § 1.482-1(a)(1).
The regulations under Section 482 implement the arm's-length standard as the governing principle for evaluating controlled transactions. Treasury Regulation § 1.482-1(b)(1) provides that, in determining the true taxable income of a controlled taxpayer, the standard to be applied in every case is that of a taxpayer dealing at arm's length with an uncontrolled taxpayer. A controlled transaction meets the arm's-length standard if the results of the transaction are consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances. Treas. Reg. § 1.482-1(b)(1). The arm's-length standard requires that controlled transactions produce results that are economically consistent with those that would have been achieved by unrelated parties acting in their own economic self-interests.
The arm's-length result is determined under the "best method rule" set forth in Treasury Regulation § 1.482-1(c). Under the best method rule, the arm's-length result of a controlled transaction must be determined under the method that, under the facts and circumstances, provides the most reliable measure of an arm's-length result. Treas. Reg. § 1.482-1(c)(1). In selecting the best method, the reliability of the result is determined by the degree of comparability between the controlled transaction and any uncontrolled comparables, and the quality of the data and assumptions used in the analysis. Id. The regulations do not establish a strict hierarchy among the specified methods; rather, the method that provides the most reliable result in a particular case is the method that should be applied. Treas. Reg. § 1.482-1(c)(2).
Additionally, the regulations provide for the establishment of an arm's-length range, which consists of the results derived from the application of a transfer pricing method to two or more uncontrolled transactions of similar comparability and reliability. Treas. Reg. § 1.482-1(e)(2). Where the controlled taxpayer's result falls within the arm's-length range, the IRS will not make an allocation under Section 482. Treas. Reg. § 1.482-1(e)(1). Conversely, where the taxpayer's result falls outside the arm's-length range, the IRS may adjust the taxpayer's result to a point within the range. Id.
III.B. Cost-Sharing Arrangements Under Treas. Reg. § 1.482-7
Treasury Regulation § 1.482-7 provides specific rules for qualified cost-sharing arrangements among controlled participants. A qualified CSA is an arrangement under which two or more controlled participants share the costs and risks of developing intangibles in proportion to their reasonably anticipated shares of the benefits from exploiting those intangibles. Treas. Reg. § 1.482-7(a), (b). A CSA that satisfies the requirements of the regulations is treated as producing results consistent with the arm's-length standard if the cost-sharing payments, PCT payments, and other terms of the arrangement are consistent with the regulations.
When a participant in a CSA makes available pre-existing resources, capabilities, or rights ("external contributions") to the CSA, the other participants must make platform contribution transaction payments to compensate the contributing participant for the value of those contributions. Treas. Reg. § 1.482-7(g). The PCT payment is the arm's-length compensation for the economic value of the external contributions made available to the CSA. The regulations contemplate that the PCT payment reflects the value of the pre-existing intangibles as of the date of the CSA, considering the income that those intangibles are reasonably anticipated to generate for the non-contributing participant.
Treasury Regulation § 1.482-7(g)(4) describes the income method for valuing PCTs. Under the income method, the PCT payment is the present value of the stream of reasonably anticipated residual divisional profits or losses from the CSA activities over the duration of the CSA activity, attributable to the external contributions. The income method requires the identification and projection of the relevant income streams, the allocation of costs and routine returns to determine residual profits attributable to the contributed intangibles, and the discounting of those residual profits to present value using an appropriate discount rate that reflects the riskiness of the projected cash flows.
The regulations also describe several other methods for valuing PCTs, including the acquisition price method (Treas. Reg. § 1.482-7(g)(5)), the market capitalization method (Treas. Reg. § 1.482-7(g)(6)), and the residual profit split method (Treas. Reg. § 1.482-7(g)(7)). The selection among these methods is governed by the best method rule of Treas. Reg. § 1.482-1(c), which requires application of the method that provides the most reliable measure of an arm's-length result under the specific facts and circumstances.
III.C. Transfer Pricing Methods for Intangible Property Under Treas. Reg. § 1.482-4
Treasury Regulation § 1.482-4 provides methods for determining the arm's-length amount charged in a controlled transaction involving the transfer of intangible property. The specified methods include the comparable uncontrolled transaction ("CUT") method (Treas. Reg. § 1.482-4(c)), the comparable profits method ("CPM") (as applied under Treas. Reg. § 1.482-5), and unspecified methods that may be applied where the specified methods do not provide a reliable measure of an arm's-length result. Treas. Reg. § 1.482-4(d).
While the primary focus of this report is the PCT valuation under Treas. Reg. § 1.482-7(g)(4), the provisions of Treas. Reg. § 1.482-4 are relevant to the related royalty arrangement for legacy IP. Specifically, certain legacy IP that was not included in the CSA is licensed by PPC to PBI under a separate intercompany license agreement at a royalty rate of 4.5% of net sales. WVG's CUT analysis of this royalty rate, discussed in Section XI below, is governed by the principles of Treas. Reg. § 1.482-4(c) and provides additional confirmation of the arm's-length nature of the PPC-PBI transfer pricing framework.
III.D. IRC § 367(d) Considerations
Section 367(d) of the Internal Revenue Code addresses certain transfers of intangible property by a United States person to a foreign corporation in an exchange described in Section 332, 351, 354, 356, or 361. Under Section 367(d), the U.S. transferor is treated as having transferred the intangible property in exchange for payments contingent on the productivity, use, or disposition of such property, and must include in income for each taxable year amounts that would be commensurate with the income attributable to the transferred intangible.
The potential application of Section 367(d) to the PPC-PBI CSA arrangement is a legal question that falls within the province of C&H as counsel. For purposes of this report, WVG notes that the IRS examination has focused its challenge on the PCT valuation under the Section 482 / CSA framework rather than seeking to recharacterize the CSA as an outbound IP transfer under Section 367(d). WVG's analysis is accordingly framed within the Section 482 / Treas. Reg. § 1.482-7 framework. To the extent the IRS were to raise a Section 367(d) recharacterization argument, the underlying economic analysis of the value of the contributed IP would remain substantially the same, although the legal consequences and the form of the adjustment might differ. WVG defers to C&H on all legal aspects of this issue.
III.E. OECD Transfer Pricing Guidelines
While the OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations do not have the force of law in the United States, they are recognized as persuasive authority in transfer pricing matters and provide a useful framework for economic analysis. See, e.g., Xilinx, Inc. v. Commissioner, 125 T.C. 37, 62 (2005) (noting that the OECD Guidelines are "an important source of interpretive guidance"), aff'd and rev'd on other grounds, 598 F.3d 1191 (9th Cir. 2010).
The OECD Transfer Pricing Guidelines, as revised in 2017 and updated in 2022, address the treatment of intangibles in Chapter VI and the treatment of cost contribution arrangements in Chapter VIII. Chapter VI introduces the concept of the "DEMPE" framework, which holds that the allocation of returns from intangibles should be based on which entity or entities perform the development, enhancement, maintenance, protection, and exploitation functions with respect to the intangible, assuming and managing the associated risks with appropriate financial capacity. The DEMPE framework is relevant to the PCT valuation insofar as it underscores the importance of analyzing PBI's functional profile — its personnel, decision-making authority, risk-bearing capacity, and operational activities — in determining the arm's-length allocation of intangible-related returns.
Chapter VIII of the OECD Guidelines addresses cost contribution arrangements, including the requirement that buy-in payments for pre-existing contributions be valued at arm's length. The principles articulated in Chapter VIII are broadly consistent with the U.S. regulatory framework under Treas. Reg. § 1.482-7, and WVG's analysis is consistent with both frameworks.
IV. DESCRIPTION OF THE PLATFORM CONTRIBUTION TRANSACTION
IV.A. CSA Structure and PCT Context
The CSA between PPC and PBI was executed effective July 1, 2012. Under the CSA, PPC and PBI agreed to share the costs and risks of developing and enhancing PPC's pharmaceutical intellectual property portfolio in proportion to their respective shares of the reasonably anticipated benefits from exploiting that portfolio in their assigned territories. PPC retained the exclusive right to develop and exploit the CSA intellectual property in the Americas, while PBI acquired the exclusive right to develop and exploit the CSA intellectual property outside the Americas (the "non-Americas" territory, encompassing EMEA and APAC markets).
In consideration for PBI's acquisition of rights in PPC's pre-existing IP portfolio as of the CSA date, PBI made two categories of payments:
(a) PCT Payment. A lump-sum platform contribution transaction payment of $312,000,000, payable on July 1, 2012, representing the arm's-length value of PBI's buy-in to PPC's pre-existing intellectual property portfolio as of that date. This payment was calculated using the income method / DCF approach as set forth in the contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP.
(b) Ongoing Cost-Sharing Payments. Ongoing payments by PBI of its proportionate share of the qualified research and development costs incurred under the CSA, calculated annually based on PBI's share of the reasonably anticipated benefits from the CSA activity. PBI's share of RAB, and thus its share of annual qualified R&D costs, was determined each year based on projected revenue allocations between the Americas and non-Americas territories.
The PCT payment is the subject of the IRS's challenge and is the focus of this report. The ongoing cost-sharing payments are addressed only to the extent relevant to the overall consistency analysis.
IV.B. Pre-Existing IP Portfolio Contributed
As of the PCT date of July 1, 2012, PPC's pre-existing IP portfolio included pharmaceutical compounds at various stages of development and commercialization. The portfolio represented the accumulated results of PPC's research and development investment over more than a decade, including extensive pre-clinical and clinical work, regulatory filings, and early-stage commercial activities. The key products in the portfolio at the contribution date are described below.
Veritaxol (Oncology). Veritaxol is a first-in-class small-molecule inhibitor targeting a novel oncogenic pathway, initially developed for the treatment of advanced non-small cell lung cancer ("NSCLC") and subsequently approved for additional oncology indications. At the PCT date, Veritaxol had received U.S. FDA approval for its initial indication (first-line treatment of EGFR-mutation-positive NSCLC) in October 2011 and was in the early stages of commercialization in the United States. Regulatory filings in the European Union, Japan, and other non-Americas markets were either pending or in preparation. As of July 1, 2012, Veritaxol had generated approximately $180 million in cumulative U.S. net sales since launch and was projected to achieve significant growth as additional markets were accessed and additional indications were pursued. By 2020, Veritaxol had become PPC's blockbuster product, generating global net sales of $3.12 billion, of which $1.34 billion (approximately 43%) was attributable to non-Americas markets.
Imvara (Immunology). Imvara is a biologic agent developed for the treatment of moderate-to-severe autoimmune conditions, including rheumatoid arthritis and psoriatic arthritis. At the PCT date, Imvara was in late-stage development, with a pivotal Phase III clinical trial underway and top-line data expected in the second half of 2013. The Phase III program involved approximately 2,400 patients across multiple clinical sites globally. At the contribution date, Imvara's future commercial success was uncertain, as the Phase III trial had not yet read out and the compound faced competition from established biologic therapies. Accordingly, probability-adjusted revenue projections were applied in the original PCT valuation, reflecting the clinical and regulatory risk inherent in a Phase III compound. Imvara subsequently received FDA approval in 2015 and achieved global net sales of $1.87 billion by 2020, of which $790 million (approximately 42%) was attributable to non-Americas markets.
Cerulon (Rare Disease). Cerulon is an enzyme replacement therapy developed for the treatment of a specific lysosomal storage disorder, a rare genetic condition affecting an estimated 5,000 to 8,000 patients globally. At the PCT date, Cerulon was in early-stage development, having completed preclinical studies and initial Phase I/II clinical evaluation. The compound had received orphan drug designation from the FDA but was several years away from potential regulatory approval. The probability of clinical and regulatory success for a compound at this stage of development was substantially lower than for Veritaxol or Imvara, and the revenue projections for Cerulon in the original PCT valuation reflected significant probability discounts. Cerulon received regulatory approvals in the United States, European Union, and Japan between 2016 and 2018, and achieved global net sales of $620 million by 2020, of which $280 million (approximately 45%) was attributable to non-Americas markets.
Other Pipeline Compounds. The contributed IP portfolio also included several additional compounds in pre-clinical and early clinical stages of development. These compounds were individually smaller in projected value and carried higher development risk. In the aggregate, they contributed modestly to the overall PCT valuation after probability weighting. WVG's analysis includes these compounds in the revenue projections and DCF model, consistent with the approach taken in the original contemporaneous valuation.
In addition to the compounds included in the CSA, certain legacy IP was licensed separately by PPC to PBI under an intercompany license agreement at a royalty rate of 4.5% of net sales. The legacy IP included certain older branded products that were already commercially established at the time of PBI's incorporation and were not included in the CSA cost-sharing framework. The legacy IP royalty arrangement is not part of the PCT valuation but is contextually relevant and is addressed in WVG's separate CUT analysis, cross-referenced in Section XI of this report.
IV.C. Cost-Sharing Ratios
Under the CSA, PBI's annual share of qualified R&D costs is determined based on its share of the reasonably anticipated benefits from the CSA activity, measured by projected revenue allocations between PPC (Americas) and PBI (non-Americas). As PBI's non-Americas commercial operations expanded and revenues grew, PBI's RAB share — and thus its cost-sharing percentage — increased over time. The following table summarizes PBI's cost-sharing percentages and payments for the examination years:
The IRS's proposed adjustments for the 2017–2020 tax years include, among other things, a recharacterization of PBI's cost-sharing ratios based on the IRS's assertion that the PCT was undervalued by $540 million. The IRS contends that if the PCT had been valued at $852 million, the cost-sharing ratios should have been recalibrated to reflect a different allocation of residual profits between PPC and PBI. WVG's analysis demonstrates that the cost-sharing ratios as applied are consistent with an arm's-length PCT valuation of $312 million and are not subject to adjustment.
IV.D. PBI's Functional Profile
A key element of both the PCT valuation and the broader transfer pricing analysis is the functional profile of PBI — the functions it performs, the assets it employs, and the risks it assumes in the non-Americas territories. WVG's analysis of PBI's functional profile is based on a review of PBI's organizational structure, headcount data, board minutes, regulatory expenditure records, and other operational documentation, as well as discussions with C&H and PPC personnel.
Personnel and Operations. PBI maintained its principal office at Sandyford Business Park, Dublin, occupying approximately 18,000 square feet of office space. PBI's headcount grew from 52 employees at inception (2012) to 185 employees by 2020. PBI's workforce included professionals in regulatory affairs, medical affairs, commercial strategy, supply chain management, finance, and legal functions. Key decision-makers within PBI included the Managing Director, the Vice President of Commercial Operations, the Vice President of Regulatory Affairs, and the Vice President of Medical Affairs, all of whom were based in Dublin and reported to PBI's board of directors.
Decision-Making Authority. PBI exercised meaningful decision-making authority over the commercialization of CSA products in the non-Americas territory. Specifically, PBI was responsible for pricing decisions, market entry strategy, selection and management of distribution partners, regulatory submission strategy and timing, and medical affairs activities across 68 country markets. PBI's board of directors held 42 meetings in Dublin over the 2017–2020 period, at which key commercial and operational decisions were discussed and approved. Board meeting minutes reviewed by WVG confirm that PBI's board was actively engaged in strategic oversight and was not merely ratifying decisions made by PPC in the United States.
Risk-Bearing. PBI bore the commercial and market risk associated with the non-Americas territory. This included the risk of adverse regulatory outcomes in non-U.S. jurisdictions, pricing and reimbursement risk in markets with government-controlled pricing regimes (including the EU, Japan, and other APAC markets), currency risk (PBI operated in over 20 functional currencies), and competition risk from established and generic competitors.
Regulatory Expenditures. PBI incurred cumulative regulatory expenditures of €47.2 million across non-Americas markets during the 2017–2020 period. These expenditures related to regulatory filings, post-marketing commitments, pharmacovigilance activities, and interactions with regulatory authorities in the EU (European Medicines Agency), Japan (PMDA), and other non-Americas jurisdictions.
Banking and Treasury. PBI maintained independent banking operations with Glenmore Bank Ireland plc, including operating accounts, hedging facilities, and cash management arrangements. PBI managed its own treasury function with respect to working capital, intercompany settlements, and foreign exchange hedging.
Contract Manufacturing. PBI contracted with Penterra Manufacturing Ireland Ltd. ("PMI") for the contract manufacturing of pharmaceutical products for non-Americas markets. PMI is an Irish private limited company (CRO Number 512347) located at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland, with approximately 620 employees engaged in pharmaceutical manufacturing and quality assurance operations. PBI compensated PMI at cost plus an 8% markup, consistent with arm's-length benchmarking of contract manufacturing arrangements in the pharmaceutical industry.
PBI's functional profile is consistent with that of a full-fledged commercial principal and IP-holding entity, rather than a passive holding company or conduit. This characterization is relevant to both the PCT valuation — insofar as PBI's ability to generate value from the contributed IP supports the projected revenue and profit levels — and the broader transfer pricing analysis under the DEMPE framework. WVG's conclusions regarding PBI's functional profile are further supported by the CPM/TNMM analysis discussed in Section XI.
V. VALUATION METHODOLOGY: INCOME METHOD / DCF APPROACH
V.A. Selection of the Income Method
WVG selected the income method under Treas. Reg. § 1.482-7(g)(4) as the best method for determining the arm's-length value of the PCT payment. This selection is consistent with the best method rule of Treas. Reg. § 1.482-1(c), which requires application of the method that provides the most reliable measure of an arm's-length result under the specific facts and circumstances.
The income method is appropriate for valuing the PCT in this case because the pre-existing intangibles contributed to the CSA generate identifiable income streams in the non-Americas territory that can be projected and discounted to present value. The contributed IP portfolio consists of pharmaceutical compounds with quantifiable revenue potential, for which market size estimates, clinical development probabilities, pricing assumptions, and competitive dynamics can be analyzed on a product-by-product basis. The income method allows for the direct quantification of the economic value of these income streams to PBI as the non-Americas participant, which is the conceptual framework prescribed by the regulations for PCT valuation.
WVG considered the alternative methods specified in the regulations and determined that they do not provide a more reliable measure of the arm's-length PCT value in this case, for the following reasons:
Acquisition Price Method (Treas. Reg. § 1.482-7(g)(5)). The acquisition price method determines the PCT value by reference to the price paid in an arm's-length acquisition of comparable intangible property. WVG was unable to identify any arm's-length acquisitions of pharmaceutical IP portfolios that were sufficiently comparable to the PPC contributed portfolio in terms of the therapeutic areas, development stages, geographic scope, and risk profile of the compounds involved. While pharmaceutical licensing and acquisition transactions are common, the unique composition of the contributed portfolio — including a mix of approved, Phase III, and early-stage oncology, immunology, and rare-disease compounds with specific geographic rights — precluded the identification of transactions with adequate comparability. The acquisition price method was therefore rejected as insufficiently reliable.
Market Capitalization Method (Treas. Reg. § 1.482-7(g)(6)). The market capitalization method derives the PCT value from the market capitalization of the entity to which the intangibles are contributed, adjusted for other assets and liabilities. This method is most reliable where the recipient entity is publicly traded and its market capitalization provides a transparent measure of the value of its intangible assets. PBI was not publicly traded at any relevant time, and its market value was not independently observable. While it might theoretically be possible to impute a market value for PBI based on the value of PPC's overall market capitalization and the relative value of the non-Americas business, such an approach would involve multiple layers of estimation and assumption that would reduce its reliability relative to the income method. The market capitalization method was therefore rejected.
Residual Profit Split Method (Treas. Reg. § 1.482-7(g)(7)). The residual profit split method allocates combined profits between the CSA participants based on the relative values of their respective contributions. WVG considered the residual profit split method as a potential cross-check on the income method results. While the residual profit split method can provide useful information in certain circumstances, WVG concluded that the income method provides a more reliable primary result in this case because it directly quantifies the present value of the income streams attributable to the contributed IP in the non-Americas territory, without the need for the additional allocation step required under the residual profit split method. WVG has, however, confirmed that the results of the income method are directionally consistent with a residual profit split analysis, which provides additional confidence in the reliability of the income method result.
For these reasons, WVG concluded that the income method / DCF approach is the best method for the PCT valuation and applied this method as the primary basis for its analysis.
V.B. DCF Framework
Under the income method, the PCT value equals the present value of the expected incremental cash flows attributable to the pre-existing IP from the non-Americas territory, discounted over the useful life of the contributed intangibles at an appropriate risk-adjusted rate. The general DCF framework is expressed as follows:
PCT Value = Σ [Expected Divisional Profits_t / (1 + WACC)^t] for t = 1 to n
Where:
• Expected Divisional Profits_t represents the residual divisional profits attributable to the pre-existing IP in the non-Americas territory in year t, after deducting routine returns on PBI's tangible assets and workforce contributions;
• WACC represents the weighted average cost of capital, determined based on the risk profile of the projected cash flows;
• n represents the number of years in the projection period (including any terminal value period); and
• t represents the year index, with t = 1 corresponding to the first year after the PCT date (July 1, 2012).
The key inputs to the DCF model are: (1) revenue projections for the non-Americas territory, disaggregated by product and adjusted for clinical success probabilities; (2) cost structure assumptions, including cost of goods sold, operating expenses, and routine returns; (3) terminal value and useful life assumptions; and (4) the discount rate (WACC). Each of these inputs is discussed in detail in Sections VI through VIII of this report.
The divisional profit concept is central to the income method. Divisional profit is defined as the total profit generated by PBI from the exploitation of the contributed IP in the non-Americas territory, less routine returns attributable to PBI's tangible assets (e.g., working capital, fixed assets) and routine functional contributions (e.g., the returns attributable to PBI's distribution, regulatory, and administrative functions). The residual divisional profit, after deducting these routine returns, represents the profit attributable to the contributed intangible property — that is, the value for which the PCT payment is the arm's-length compensation.
V.C. Projection Period and Useful Life
WVG employed a 15-year explicit forecast period, spanning from the PCT date (July 1, 2012) through June 30, 2027, reflecting the estimated remaining commercial life of the contributed compounds. This projection horizon was determined based on an analysis of the following factors:
Average Remaining Patent Life. As of July 1, 2012, the key compounds in the contributed portfolio had remaining patent lives ranging from approximately 8 years (for certain formulation patents on Veritaxol) to approximately 18 years (for composition-of-matter patents on Cerulon and certain pipeline compounds). The weighted average remaining patent life, considering the relative value of each compound in the portfolio, was approximately 14 years. WVG's 15-year explicit forecast period encompasses this weighted average patent life with a modest extension to account for potential patent term extensions and pediatric exclusivity periods available under U.S. and EU law.
Historical Pharmaceutical Product Lifecycles. Industry data on pharmaceutical product lifecycles indicates that branded pharmaceutical products typically experience peak revenues approximately 5 to 10 years after initial launch, followed by a gradual decline as patents expire and generic or biosimilar competition enters the market. The 15-year projection period is consistent with this lifecycle pattern for the contributed portfolio, which included products at various stages from early commercialization to early-stage development.
Terminal Value. Beyond the 15-year explicit forecast period, WVG applied a declining cash flow model to capture the residual value of the contributed IP beyond Year 15. This terminal value model assumes that revenues decline at a rate of approximately 15% to 25% per year after patent expiration, reflecting the impact of generic competition, biosimilar entry, and lifecycle decline. The terminal value is discounted to present value at the same WACC (9.8%) applied to the explicit forecast period cash flows. The declining cash flow model is more conservative than a perpetuity-based terminal value approach, which WVG considered inappropriate given the finite patent-protected life of pharmaceutical intangibles.
The 15-year projection period and declining-cash-flow terminal value methodology are consistent with industry valuation practices for pharmaceutical intangible assets, as reflected in published literature and WVG's experience in pharmaceutical IP valuations.
VI. REVENUE PROJECTIONS
VI.A. Revenue Forecasting Methodology
A critical input to the DCF model is the projection of revenues attributable to the contributed IP in the non-Americas territory over the 15-year forecast period. WVG's revenue projections were prepared as of the PCT date (July 1, 2012), based on information reasonably available at that time. This as-of-date framework is required by the regulations and is essential to the integrity of the valuation, as the arm's-length value of the PCT must be determined based on the information and expectations that would have been available to hypothetical arm's-length parties as of the transaction date, not on the basis of subsequent actual outcomes. See Treas. Reg. § 1.482-7(g)(4)(vi)(F) (the financial projections used in the income method "must be the most reliable projections . . . from the perspective of the date of the PCT").
WVG's revenue forecasting methodology involved the following steps:
1. Product-by-Product Analysis. Revenue projections were developed on a product-by-product basis for each compound included in the CSA portfolio, reflecting the specific clinical development status, regulatory pathway, competitive landscape, and market potential of each compound as of July 1, 2012.
2. Clinical Development Probability Adjustments. For compounds that were not yet approved as of the PCT date (i.e., Imvara, Cerulon, and other pipeline compounds), revenue projections were adjusted by probability-of-success factors reflecting the likelihood that each compound would successfully complete clinical development and obtain regulatory approval. These probability factors were based on published industry data regarding historical clinical trial success rates by development phase and therapeutic area, sourced from databases such as Beaumont Systems and published studies by DiMasi et al. (2010), Thomas et al. (2016), and others.
3. Market Size and Penetration Estimates. For each compound, WVG estimated the total addressable market in the non-Americas territory based on epidemiological data, current treatment paradigms, and pricing and reimbursement dynamics in key non-Americas markets (EU5, Japan, China, Brazil, and other significant markets). Market penetration rates were estimated based on the compound's projected efficacy and safety profile, competitive positioning, and expected launch timing in each market.
4. Pricing Assumptions. Pricing assumptions reflected the expected ex-manufacturer net prices in each major non-Americas market, taking into account government-controlled pricing and reimbursement systems, reference pricing mechanisms, and competitive pricing dynamics. Non-Americas prices were generally assumed to be lower than U.S. prices, consistent with observed international pharmaceutical pricing differentials.
5. Launch Timing. Projected launch dates in non-Americas markets were based on the expected timelines for regulatory submissions and approvals in the EU (EMA), Japan (PMDA), and other key markets, taking into account the typical lag between U.S. and non-U.S. approvals for pharmaceutical products.
6. Competitive Landscape Analysis. Revenue projections incorporated an assessment of the competitive landscape as of July 1, 2012, including existing and anticipated competitive products, potential generic or biosimilar entry upon patent expiration, and the expected evolution of treatment guidelines.
VI.B. Product-Level Revenue Projections
Veritaxol (Oncology). At the PCT date, Veritaxol had been approved by the FDA for approximately eight months and was in the early stages of U.S. commercialization. EU regulatory filings were in progress, with EMA approval anticipated in 2013. Japanese regulatory filings were expected to follow, with PMDA approval anticipated in 2014. Veritaxol's novel mechanism of action and promising clinical data positioned it as a potential best-in-class agent for EGFR-mutation-positive NSCLC, but the product's commercial trajectory was still uncertain given the early stage of commercialization and the presence of several established competitors in the NSCLC market.
WVG's as-of-date revenue projections for Veritaxol in the non-Americas territory assumed:
• EU launch in mid-2013, with initial market penetration building gradually as reimbursement approvals were obtained in individual EU member states;
• Japanese launch in early 2015, following PMDA approval;
• Expansion to additional APAC markets (China, South Korea, Australia) and other EMEA markets over the 2015–2018 period;
• Peak non-Americas net sales reaching approximately $1.0 billion to $1.4 billion, achievable by approximately Year 8 to Year 10 of the projection period (2020–2022);
• Subsequent decline following patent expiration, with generic entry assumed beginning in the 2023–2025 timeframe depending on the specific market and applicable patent protection.
Comparison to Actual Performance. By 2020, Veritaxol had achieved non-Americas net sales of $1.34 billion ($3.12 billion global). This actual result was within the range of WVG's as-of-date projections, though at the upper end, reflecting the product's strong commercial execution and the successful expansion of its label to additional oncology indications (including second-line NSCLC and adjuvant treatment) that were not fully anticipated at the PCT date. WVG notes that while the actual outcome is a useful reference point, it does not determine the appropriate as-of-date valuation; the valuation must be based on what was reasonably anticipated as of July 1, 2012.
Imvara (Immunology). At the PCT date, Imvara was in late-stage development, with a pivotal Phase III clinical trial underway. The Phase III trial was a large, multi-center, randomized controlled trial evaluating Imvara versus placebo in patients with moderate-to-severe rheumatoid arthritis who had experienced inadequate response to methotrexate. Enrollment had been completed, and top-line data were expected in the second half of 2013. While the preclinical and Phase I/II data for Imvara were encouraging, the outcome of the Phase III trial was uncertain as of the PCT date, and there was a meaningful risk that the trial would not meet its primary endpoint or would produce safety signals that could delay or prevent regulatory approval.
WVG's as-of-date revenue projections for Imvara applied a clinical success probability factor of approximately 55% to 65%, reflecting the historical probability of success for biologic compounds in Phase III clinical trials in the immunology therapeutic area. This probability factor was applied to the unadjusted (pre-probability) revenue projections to produce probability-weighted revenue estimates.
WVG's projections assumed:
• Probability-adjusted U.S. approval in 2015, with EU and Japanese approvals following approximately 12 to 18 months later;
• Non-Americas launches commencing in 2016 (EU) and 2017 (Japan);
• Peak probability-adjusted non-Americas net sales reaching approximately $550 million to $750 million by approximately Year 10 to Year 12 of the projection period;
• Revenue decline following loss of exclusivity, with biosimilar entry assumed beginning approximately 12 to 14 years after initial launch.
Comparison to Actual Performance. Imvara successfully completed its Phase III trial, received FDA approval in 2015, and achieved non-Americas net sales of $790 million by 2020 ($1.87 billion global). The actual outcome exceeded the probability-weighted projections, as would be expected when a clinical-stage compound is ultimately approved and commercialized. The unadjusted (pre-probability) revenue projections were generally consistent with the actual outcome, confirming that the underlying market assumptions were reasonable.
Cerulon (Rare Disease)
At the PCT date, Cerulon was in early-stage clinical development, having completed initial Phase I/II studies in a small number of patients. The compound had received orphan drug designation from the FDA, which provided certain regulatory and commercial advantages (including market exclusivity and potential fast-track review), but was several years away from potential regulatory approval. The clinical development pathway for Cerulon involved additional Phase II and Phase III studies, which were expected to take approximately four to six years to complete. The probability of a compound at this stage successfully reaching regulatory approval was significantly lower than for a compound already in Phase III.
WVG applied a cumulative clinical success probability factor of approximately 20% to 30% to the Cerulon revenue projections, reflecting the historical probability of success for enzyme replacement therapies transitioning from Phase I/II through regulatory approval. This probability weighting substantially reduced the contribution of Cerulon to the overall PCT valuation, which is appropriate given the high level of development risk inherent in an early-stage compound.
WVG's probability-weighted projections for Cerulon assumed:
• Probability-adjusted first regulatory approval in the 2017–2019 timeframe;
• Non-Americas launches commencing approximately 12 to 24 months after initial approval;
• Peak probability-adjusted non-Americas net sales reaching approximately $80 million to $150 million;
• Revenue persistence over a longer period than the oncology and immunology compounds, reflecting the limited competition and orphan drug exclusivity typically associated with rare-disease therapeutics.
Comparison to Actual Performance. Cerulon received regulatory approvals in the United States, European Union, and Japan between 2016 and 2018 and achieved non-Americas net sales of $280 million by 2020 ($620 million global). As with Imvara, the actual outcome exceeded the probability-weighted projections, which is the expected result when a high-risk compound is ultimately successful.
Other Pipeline Compounds
The contributed IP portfolio included several additional compounds in pre-clinical and early clinical stages of development. Given the very early stage of these compounds, WVG applied cumulative clinical success probability factors of approximately 5% to 15%, depending on the specific compound's development stage and therapeutic area. In aggregate, these compounds contributed modestly to the overall PCT valuation after probability weighting. WVG's revenue projections for these compounds are set forth in the product-level revenue projection summary in Exhibit 8.
VI.C. Comparison of WVG Projections to IRS Projections
The IRS economist, Dr. Alan Washburne, developed revenue projections as part of the IRS's income-method valuation that differ materially from WVG's projections. WVG has identified the following principal areas of disagreement:
Higher Revenue Growth Assumptions. Dr. Washburne's projections assume higher revenue growth rates for the contributed compounds in the non-Americas territory, particularly in the early years of the projection period. In several cases, the IRS's assumed growth rates exceed the upper bound of the range that WVG considers reasonable based on information available as of July 1, 2012.
Lower Risk Adjustments for Clinical-Stage Compounds. Dr. Washburne applied materially lower probability-of-success discounts to the revenue projections for compounds in clinical development as of the PCT date. For Imvara (Phase III), Dr. Washburne applied a clinical success probability of approximately 80%, compared to WVG's range of 55% to 65%. For Cerulon (early-stage), Dr. Washburne applied a cumulative probability of approximately 45%, compared to WVG's range of 20% to 30%. These higher probability assumptions have the effect of significantly increasing the projected revenue contribution of clinical-stage compounds, thereby inflating the PCT value.
Inadequate Accounting for Competitive and Generic Entry Risks. Dr. Washburne's projections do not adequately account for the risk of competitive entry from established competitors, new entrants, or generic/biosimilar products following patent expiration. The IRS projections assume longer periods of peak revenue and more gradual post-patent revenue decline than WVG considers supportable based on pharmaceutical indu

I. EXECUTIVE SUMMARY

II. ENGAGEMENT AND SCOPE

III. LEGAL AND REGULATORY FRAMEWORK

IV. DESCRIPTION OF THE PLATFORM CONTRIBUTION TRANSACTION

V. VALUATION METHODOLOGY: INCOME METHOD / DCF APPROACH

VI. REVENUE PROJECTIONS

Record

Parties

Dates

Amounts